NZ540340A - 2-(1H-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases - Google Patents
2-(1H-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseasesInfo
- Publication number
- NZ540340A NZ540340A NZ540340A NZ54034003A NZ540340A NZ 540340 A NZ540340 A NZ 540340A NZ 540340 A NZ540340 A NZ 540340A NZ 54034003 A NZ54034003 A NZ 54034003A NZ 540340 A NZ540340 A NZ 540340A
- Authority
- NZ
- New Zealand
- Prior art keywords
- indazol
- compound
- ylamino
- pyridin
- mmol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43490202P | 2002-12-19 | 2002-12-19 | |
| PCT/IB2003/005854 WO2004056806A1 (en) | 2002-12-19 | 2003-12-08 | 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ540340A true NZ540340A (en) | 2007-07-27 |
Family
ID=32682122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ540340A NZ540340A (en) | 2002-12-19 | 2003-12-08 | 2-(1H-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US7053107B2 (de) |
| EP (1) | EP1585743B1 (de) |
| JP (1) | JP3814285B2 (de) |
| KR (1) | KR100730267B1 (de) |
| CN (1) | CN1747950A (de) |
| AP (1) | AP2005003341A0 (de) |
| AR (1) | AR042510A1 (de) |
| AT (1) | ATE362928T1 (de) |
| AU (1) | AU2003286321A1 (de) |
| BR (1) | BR0317548A (de) |
| CA (1) | CA2510850A1 (de) |
| CO (1) | CO5580767A2 (de) |
| CR (1) | CR7882A (de) |
| DE (1) | DE60314013T2 (de) |
| DK (1) | DK1585743T3 (de) |
| EA (1) | EA008501B1 (de) |
| EC (1) | ECSP055858A (de) |
| GT (1) | GT200300294A (de) |
| HR (1) | HRP20050559A2 (de) |
| IS (1) | IS7859A (de) |
| MA (1) | MA27570A1 (de) |
| MX (1) | MXPA05006676A (de) |
| NL (1) | NL1025073C2 (de) |
| NO (1) | NO20053486L (de) |
| NZ (1) | NZ540340A (de) |
| OA (1) | OA12977A (de) |
| PA (1) | PA8592901A1 (de) |
| PE (1) | PE20041006A1 (de) |
| PL (1) | PL377713A1 (de) |
| PT (1) | PT1585743E (de) |
| RS (1) | RS20050430A (de) |
| SI (1) | SI1585743T1 (de) |
| TN (1) | TNSN05164A1 (de) |
| TW (1) | TW200424193A (de) |
| UY (1) | UY28130A1 (de) |
| WO (1) | WO2004056806A1 (de) |
| ZA (1) | ZA200504339B (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| WO2005094823A1 (ja) * | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | Ｆｌｔ－３阻害剤 |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| WO2006043172A1 (en) * | 2004-10-19 | 2006-04-27 | Pfizer Inc. | Pharmaceutical compositions and methods for sub-tenon delivery |
| AU2005300311A1 (en) * | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Methods for preparing indazole compounds |
| US20060160863A1 (en) * | 2005-01-05 | 2006-07-20 | Agouron Pharmaceuticals, Inc. | Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide |
| WO2006117666A2 (en) * | 2005-04-29 | 2006-11-09 | Pfizer Inc. | Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery |
| US8340944B2 (en) | 2005-11-30 | 2012-12-25 | The Invention Science Fund I, Llc | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| US10296720B2 (en) | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US8000981B2 (en) | 2005-11-30 | 2011-08-16 | The Invention Science Fund I, Llc | Methods and systems related to receiving nutraceutical associated information |
| US8297028B2 (en) | 2006-06-14 | 2012-10-30 | The Invention Science Fund I, Llc | Individualized pharmaceutical selection and packaging |
| US20080103746A1 (en) * | 2005-11-30 | 2008-05-01 | Searete Llc, A Limited Liability Corporation | Systems and methods for pathogen detection and response |
| US7974856B2 (en) | 2005-11-30 | 2011-07-05 | The Invention Science Fund I, Llc | Computational systems and methods related to nutraceuticals |
| US7827042B2 (en) | 2005-11-30 | 2010-11-02 | The Invention Science Fund I, Inc | Methods and systems related to transmission of nutraceutical associated information |
| US7927787B2 (en) | 2006-06-28 | 2011-04-19 | The Invention Science Fund I, Llc | Methods and systems for analysis of nutraceutical associated components |
| MX2008010193A (es) * | 2006-02-10 | 2008-11-27 | Summit Corp Plc | Tratamiento de distrofia muscular de duchenne. |
| WO2008020606A1 (fr) * | 2006-08-16 | 2008-02-21 | Kyowa Hakko Kirin Co., Ltd. | Agent anti-angiogénique |
| WO2008128538A1 (en) * | 2007-04-19 | 2008-10-30 | Leo Pharma A/S | Src family kinase inhibitors |
| JP5371953B2 (ja) | 2007-04-20 | 2013-12-18 | アキュセラ インコーポレイテッド | 眼の疾患及び障害を治療するスチレニル誘導体化合物 |
| US20090081277A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
| KR20110045095A (ko) | 2008-08-27 | 2011-05-03 | 레오 파마 에이/에스 | Ｖｅｇｆｒ-2 수용체 및 단백질 티로신 키나아제 억제제인 피리딘 유도체 |
| CN103804349A (zh) * | 2012-11-01 | 2014-05-21 | 杨子娇 | 一类治疗青光眼的化合物及其用途 |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| EP3127900B1 (de) * | 2014-03-31 | 2017-10-18 | Senju Pharmaceutical Co., Ltd. | Alkynylindazolderivat und verwendung davon |
| CN104744338A (zh) * | 2015-03-31 | 2015-07-01 | 天津维智精细化工有限公司 | 一种6-氯羟吲哚的合成方法 |
| US10519133B2 (en) * | 2015-08-07 | 2019-12-31 | Medshine Discovery Inc. | Vinyl compounds as FGFR and VEGFR inhibitors |
| CN109942544B (zh) * | 2017-12-21 | 2021-06-11 | 中国科学院合肥物质科学研究院 | 一类新型吲唑类衍生物激酶抑制剂 |
| WO2024032584A1 (zh) * | 2022-08-08 | 2024-02-15 | 苏州必扬医药科技有限公司 | 一种蛋白酪氨酸激酶抑制剂及其医疗用途 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| EP0625200B1 (de) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Marker für krebs und biosynthetisches bindeprotein dafür |
| US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| CN1165482A (zh) | 1994-11-10 | 1997-11-19 | 科西雷佩蒂斯公司 | 用作蛋白激酶抑制剂的吡唑药物组合物 |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| DE69519751T2 (de) | 1995-04-20 | 2001-04-19 | Pfizer | Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
| DE69734149T2 (de) | 1996-03-15 | 2006-07-06 | Astrazeneca Ab | Cinoline derivate und verwendung als heilmittel |
| EP0907649A1 (de) | 1996-06-27 | 1999-04-14 | Pfizer Inc. | 2-(2-oxo-ethyliden)-imidazolidin-4-one-derivate und ihre verwendung als inhibitoren des farnesyl-protein-transferase |
| EP0818442A3 (de) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclische Sulphonderivate als Metalloproteinase-Inhibitoren und zur Hemmung der Produktion von Tumornekrosefaktor |
| AU3766897A (en) | 1996-07-13 | 1998-02-09 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| BR9710362A (pt) | 1996-07-13 | 1999-08-17 | Glaxo Group Ltd | Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto |
| WO1998003516A1 (en) | 1996-07-18 | 1998-01-29 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| SK21499A3 (en) | 1996-08-23 | 2000-05-16 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
| EP0977733B1 (de) | 1997-02-03 | 2003-09-03 | Pfizer Products Inc. | Arylsulfonylhydroxamsäurederivate |
| CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| CN1247531A (zh) | 1997-02-11 | 2000-03-15 | 辉瑞大药厂 | 芳基磺酰基异羟肟酸衍生物 |
| ATE292623T1 (de) | 1997-05-07 | 2005-04-15 | Sugen Inc | 2-indolinonderivate als modulatoren der proteinkinase-ativität |
| CA2291709A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| US6658447B2 (en) * | 1997-07-08 | 2003-12-02 | Intel Corporation | Priority based simultaneous multi-threading |
| ID23668A (id) | 1997-08-08 | 2000-05-11 | Pfizer Prod Inc | Turunan asam ariloksiarilsulfonilamino hidroksamat |
| DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| EP1017682A4 (de) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | Neue angiogenese-inhibitoren |
| KR100446363B1 (ko) | 1997-11-11 | 2004-09-01 | 화이자 프로덕츠 인코포레이티드 | 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체 |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| JPH11236333A (ja) | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−４−オン誘導体 |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| EP1082305A4 (de) | 1998-05-29 | 2001-09-26 | Sugen Inc | Pyrrol substituierte 2-indolinone wirksam als proteinkinase-hemmer |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| CA2341690C (en) | 1998-08-27 | 2007-04-17 | Pfizer Products Inc. | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents |
| ES2237125T3 (es) | 1998-08-27 | 2005-07-16 | Pfizer Products Inc. | Derivados de quinolin-2-ona utiles como agentes anticancerigenos. |
| US6114361A (en) | 1998-11-05 | 2000-09-05 | Pfizer Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| EP1006113A1 (de) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | 2-(2-oxo-ethyliden)-imidazolidin-4-one-Derivate und ihre Verwendung zur Inhibierung des abnormalen Zellwachstums |
| JP2002533416A (ja) | 1998-12-23 | 2002-10-08 | ジー．ディー．サール ＆ カンパニー | 新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−２インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法 |
| US6649645B1 (en) | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| CZ20012910A3 (cs) | 1999-02-11 | 2002-02-13 | Pfizer Products Inc. | Heteroarylem-substituované chinolin-2-onové deriváty pouľitelné jako protinádorové prostředky |
| US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
| US6511993B1 (en) | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| EP1081137A1 (de) | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selektive Inhibitoren von Aggrecanase zur Behandlung von Osteoarthritis |
| JP2001121829A (ja) * | 1999-10-26 | 2001-05-08 | Sony Chem Corp | 情報記録用シート |
| ES2212971T3 (es) | 1999-11-30 | 2004-08-16 | Pfizer Products Inc. | Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa. |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| YU54202A (sh) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
| US6844357B2 (en) | 2000-05-01 | 2005-01-18 | Pfizer Inc. | Substituted quinolin-2-one derivatives useful as antiproliferative agents |
| AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
-
2003
- 2003-12-08 CA CA002510850A patent/CA2510850A1/en not_active Abandoned
- 2003-12-08 NZ NZ540340A patent/NZ540340A/en unknown
- 2003-12-08 KR KR1020057011551A patent/KR100730267B1/ko not_active IP Right Cessation
- 2003-12-08 EA EA200500811A patent/EA008501B1/ru not_active IP Right Cessation
- 2003-12-08 AT AT03777064T patent/ATE362928T1/de not_active IP Right Cessation
- 2003-12-08 CN CNA2003801096976A patent/CN1747950A/zh active Pending
- 2003-12-08 WO PCT/IB2003/005854 patent/WO2004056806A1/en active IP Right Grant
- 2003-12-08 RS YUP-2005/0430A patent/RS20050430A/sr unknown
- 2003-12-08 MX MXPA05006676A patent/MXPA05006676A/es unknown
- 2003-12-08 PT PT03777064T patent/PT1585743E/pt unknown
- 2003-12-08 BR BR0317548-0A patent/BR0317548A/pt not_active IP Right Cessation
- 2003-12-08 AU AU2003286321A patent/AU2003286321A1/en not_active Abandoned
- 2003-12-08 DE DE60314013T patent/DE60314013T2/de not_active Expired - Fee Related
- 2003-12-08 DK DK03777064T patent/DK1585743T3/da active
- 2003-12-08 OA OA1200500188A patent/OA12977A/en unknown
- 2003-12-08 AP AP2005003341A patent/AP2005003341A0/xx unknown
- 2003-12-08 SI SI200330833T patent/SI1585743T1/sl unknown
- 2003-12-08 PL PL377713A patent/PL377713A1/pl not_active Application Discontinuation
- 2003-12-08 EP EP03777064A patent/EP1585743B1/de not_active Expired - Lifetime
- 2003-12-08 JP JP2004561821A patent/JP3814285B2/ja not_active Expired - Fee Related
- 2003-12-11 PE PE2003001269A patent/PE20041006A1/es not_active Application Discontinuation
- 2003-12-15 US US10/737,655 patent/US7053107B2/en not_active Expired - Fee Related
- 2003-12-17 UY UY28130A patent/UY28130A1/es not_active Application Discontinuation
- 2003-12-17 PA PA20038592901A patent/PA8592901A1/es unknown
- 2003-12-17 AR ARP030104683A patent/AR042510A1/es unknown
- 2003-12-18 GT GT200300294A patent/GT200300294A/es unknown
- 2003-12-18 NL NL1025073A patent/NL1025073C2/nl not_active IP Right Cessation
- 2003-12-18 TW TW092135955A patent/TW200424193A/zh unknown
-
2005
- 2005-05-23 IS IS7859A patent/IS7859A/is unknown
- 2005-05-27 ZA ZA200504339A patent/ZA200504339B/en unknown
- 2005-06-15 EC EC2005005858A patent/ECSP055858A/es unknown
- 2005-06-16 HR HR20050559A patent/HRP20050559A2/hr not_active Application Discontinuation
- 2005-06-17 CO CO05059483A patent/CO5580767A2/es not_active Application Discontinuation
- 2005-06-17 CR CR7882A patent/CR7882A/es not_active Application Discontinuation
- 2005-06-17 MA MA28348A patent/MA27570A1/fr unknown
- 2005-06-17 TN TNP2005000164A patent/TNSN05164A1/fr unknown
- 2005-07-18 NO NO20053486A patent/NO20053486L/no not_active Application Discontinuation
- 2005-12-16 US US11/305,811 patent/US20060160858A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1585743B1 (de) | 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten | |
| AU777701B2 (en) | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | |
| US6531491B1 (en) | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | |
| US6462069B2 (en) | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases | |
| US7141581B2 (en) | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |